CORMEDIX INC. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
CORMEDIX INC. (CRMD) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $1.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-05-14
- CORMEDIX INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was $1.00K, a 83.33% decline year-over-year.
- CORMEDIX INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-12-31 was -$994.00, a 150.00% decline year-over-year.
- CORMEDIX INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-09-30 was $8.21K, a 142.11% increase year-over-year.
- CORMEDIX INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-06-30 was -$5.12K, a 325.59% decline year-over-year.
- CORMEDIX INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was -$4.00K.
- CORMEDIX INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was -$3.00K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.00K 10-Q · filed 2026-05-14 | $6.00 derived: sum of 2 quarters · filed 2026-05-14 | $8.21K derived: sum of 3 quarters · filed 2026-05-14 | $3.09K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | -$994.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $7.21K derived: sum of 2 quarters · filed 2026-03-05 | $2.09K derived: sum of 3 quarters · filed 2026-03-05 | -$4.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $8.21K 10-Q · filed 2025-11-12 | $3.08K derived: sum of 2 quarters · filed 2025-11-12 | -$3.01K 10-Q · filed 2025-11-12 | $11.07K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-06-30 | -$5.12K 10-Q · filed 2025-08-07 | -$11.21K 10-Q · filed 2025-08-07 | $2.87K derived: sum of 3 quarters · filed 2026-05-14 | $6.26K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-03-31 | $6.00K 10-Q · filed 2026-05-14 | $7.99K derived: sum of 2 quarters · filed 2026-05-14 | $11.38K derived: sum of 3 quarters · filed 2026-05-14 | $13.65K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.99K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.38K derived: sum of 2 quarters · filed 2026-03-05 | $7.65K derived: sum of 3 quarters · filed 2026-03-05 | -$3.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.39K 10-Q · filed 2025-11-12 | $5.66K derived: sum of 2 quarters · filed 2025-11-12 | -$4.99K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $2.27K 10-Q · filed 2025-08-07 | -$8.38K 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |